RadNet
RDNT · NASDAQ · Healthcare
$76.00
$1.74 (-2.29%) today
Market Cap
$5.98B
24h Volume
$97.6M
P/E Ratio
0.0
52w High
$84.48
52w Low
$51.87
Est. AI Revenue
5%
7-Day Sparkline (Static)
Company facts
Performance
About RadNet
RadNet operates the largest network of outpatient imaging centers in the United States, performing MRI, CT, PET, mammography, and other diagnostic scans across hundreds of locations. It earns revenue from insurers, health systems, and patients for each procedure, plus a growing stream of software and AI revenue from its Digital Health segment.
That segment is built around DeepHealth, which sells AI tools for breast, lung, and prostate cancer screening. Products include SmartMammo and the Enhanced Breast Cancer Detection program offered directly to patients. The 2025 acquisition of iCAD brought the ProFound AI mammography portfolio in house and consolidated a large share of the imaging AI market under one roof.
Founded in 1980 and headquartered in Los Angeles, California, RadNet employs about 11,000 people and trades on the NASDAQ under the ticker RDNT.
RadNet in the AI buildout
RadNet sits in the AI Healthcare layer of the buildout. It is both a deployer and a vendor of clinical AI: its imaging centers generate the scan volumes that validate screening algorithms, and its DeepHealth segment packages those algorithms into products sold to patients, radiologists, and health systems. Its exposure grows as AI screening moves from an add-on service to a standard part of the imaging workflow, giving the company a credible path to AI-led margins on top of procedure revenue.
RDNT is tracked in AI Healthcare, rated Growing on the AI Exposure leaderboard.
By the numbers
52-week range
RDNT trades at $76.00, 74% of the way up its 52-week range of $51.87 to $84.48.
Market cap
Market capitalization is $5.98B, with an AI Exposure Score of 45 out of 100.
Next earnings
RadNet is next expected to report earnings on November 5, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does RadNet do?
RadNet runs the largest US outpatient imaging network, performing MRI, CT, PET, and mammography scans. Its Digital Health segment, anchored by DeepHealth, develops AI software for cancer screening and imaging workflow, sold to patients, radiologists, and health systems.
How is RadNet exposed to AI?
Supercycle rates RadNet as Growing with an AI Exposure Score of 45 out of 100. AI screening is its fastest developing business, but most revenue still comes from imaging procedures, so exposure is meaningful and rising rather than dominant.
What AI products does RadNet own?
RadNet's DeepHealth segment offers SmartMammo for mammography plus AI screening tools for lung and prostate cancer, and the Enhanced Breast Cancer Detection program. The 2025 iCAD acquisition added the ProFound AI portfolio of FDA-cleared breast AI products.
Who leads RadNet?
Howard Berger, a co-founder of the company, serves as chief executive. He has led RadNet since its early days in Los Angeles, building it from a local radiology operation into a national network with about 11,000 employees.
Is RDNT a pure play AI stock?
No. RadNet is a Growing tier stock in the Supercycle framework. The core business is physical imaging centers, with AI as an attached, fast-growing segment. Pure play status is reserved for companies whose business exists because of AI demand.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.